^
    2years
    Veracyte announces three abstracts to be presented at SITC 2022 annual meeting (Veracyte Press Release)
    "Veracyte...announced today that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs (SITC 2022), taking place November 8-12, 2022, in Boston."
    Clinical data
    |
    Brightplex® MDSC Assay • Immunoscore® TCE test
    2years
    Brightplex TCE and Brightplex MDSC assays combination improves advanced NSCLC patients' stratification under anti-PD1/L1 immunotherapy in the PIONeeR project (SITC 2022)
    Interestingly, in the 17 “Cold tumors”, high infiltration of PMN-MDSC and granulocytes also identified 5 patients with worse prognostic: at 2.5 months, only 20% PFS vs 58% in the low-density group (NS) (table 1). Conclusions Brightplex® TCE and MDSC assays in combination allowed the stratification of advanced NSCLC patients in 5 subgroups, among which two subgroups with poor outcome and no responder, representing 45% of the total population that would likely not benefit from anti-PD1/L1 monotherapy.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    Brightplex® MDSC Assay • Immunoscore® TCE test